Kanti Rai's guest appearances

Kanti Rai

HMP CME (Video)

EHA Hematology Podcast

HMP CME (Audio)

2012 American Society of Hematology (ASH) Annual Meeting

Sonia Friedman

Robert Sidbury

Jonathan Kay

Richard Kim

Stanley Cohen

Matt S

Atopic Dermatitis

Axel Grothey

Tanios Bekaii-Saab

Ghassan Abou-Alfa

Heinz-Josef Lenz

Rakesh Jain

Josep Tabernero

Jean-Yves Douillard

John Cooper

OwlTail

Webcast: Navigating the Evolving Therapeutic Landscape of CLL: Strategies for the Optimal Application of Emerging Agents and Combinations in Practice

Kanti Rai, MD: Changing treatment paradigm for CLL over the years

John Gribben

Professor John Gribben from Barts and The London Trust Cancer Centre, UK, is joined by Professor Peter Hillman from St James’s University Hospital, Leeds, UK, and Professor Kanti Rai from Long Island Jewish Medical Center, New York, USA, at ASH 2012 to talk to ecancer.TV about the exciting times being witnessed in CLL and the new data presented at the meeting. Professor Rai points to the “astounding” advances that have been made in CLL over the past 4-5 years based on improved understanding of the molecular biology of the disease, eg, the B-cell receptor and signalling pathways, that have led to the development of the PTK inhibitors and the PI3 kinase inhibitors.  These new drug groups have given previously refractory patients new hope although Professor Rai comments on the caution still required concerning durability of response with ibrutinib and GS1101 as single versus combination agents.  He also comments on the chemo-free approach to treatment and when this might be an appropriate therapeutic option. Professor Hillman notes the impressive and sustained response rates seen with some of these newer agents, and comments on the hope of cure of CLL in the future.  Professor Hillman also notes the promise for the combined use of monoclonal antibodies with newer agents.  The experts discuss the importance of educating patients on the expected response to newer agents, eg, on speed of response and lymphocytosis, and note from new data presented at ASH 2012 that many questions remain on the mechanism of action of newer agents.  They also comment on promising new data being presented with Bcl-2 inhibitors and the challenge of getting all the new agents into logical clinical trial development programmes to speed effective agents to market as safely and rapidly as possible. Finally, the experts discuss the importance of the variety of patients being treated in clinical trials, eg, elderly, younger fitter patients and previously refractory patients.

Professor John Gribben from Barts and The London Trust Cancer Centre, UK, is joined by Professor Peter Hillman from St James’s University Hospital, Leeds, UK, and Professor Kanti Rai from Long Island Jewish Medical Center, New York, USA, at ASH 2012 to talk to <a href="http://ecancer.TV" rel="nofollow" target="_blank">ecancer.TV</a> about the exciting times being witnessed in CLL and the new data presented at the meeting. Professor Rai points to the “astounding” advances that have been made in CLL over the past 4-5 years based on improved understanding of the molecular biology of the disease, eg, the B-cell receptor and signalling pathways, that have led to the development of the PTK inhibitors and the PI3 kinase inhibitors. These new drug groups have given previously refractory patients new hope although Professor Rai comments on the caution still required concerning durability of response with ibrutinib and GS1101 as single versus combination agents. He also comments on the chemo-free approach to treatment and when this might be an appropriate therapeutic option. Professor Hillman notes the impressive and sustained response rates seen with some of these newer agents, and comments on the hope of cure of CLL in the future. Professor Hillman also notes the promise for the combined use of monoclonal antibodies with newer agents. The experts discuss the importance of educating patients on the expected response to newer agents, eg, on speed of response and lymphocytosis, and note from new data presented at ASH 2012 that many questions remain on the mechanism of action of newer agents. They also comment on promising new data being presented with Bcl-2 inhibitors and the challenge of getting all the new agents into logical clinical trial development programmes to speed effective agents to market as safely and rapidly as possible. Finally, the experts discuss the importance of the variety of patients being treated in clinical trials, eg, elderly, younger fitter patients and previously refractory patients.

Expert overview of CLL: Professor John Gribben, Professor Peter Hillman, Professor Kanti Rai